10th Annual Advanced Liver Disease &
Liver Transplantation Update 2015
Thank you to the Gift of Life Foundation for providing funding toward this course.
Friday, May 8, 2015
7:30 am - 3:15 pm
Sheraton Detroit Novi Hotel
21111 Haggerty Road
Novi, MI 48375
P (248) 349-4000
F (248) 349-4066
This course is directed to gastroenterologists, primary care physicians, surgeons and other health care providers including nurse practitioners, social workers, physician assistants and nurses involved in the management of patients with cirrhosis and advanced liver disease.
Registration fees include refreshments and educational materials. You are urged to register as soon as you are certain of attending as we cannot guarantee educational materials for participants who are not preregistered by April 24, 2015. Checks (in U.S. currency) must be payable to the University of Michigan. American Express, Mastercard, Visa and Discover are also accepted. Payment is due at time of registration.
U-M Faculty & Staff Rate
Please call (734) 936-7093 to register.
University of Michigan Transplant Center
300 North Ingalls Street, Room 5D17
Ann Arbor, MI 48109-5415
The registration fee is non-refundable.
This course is designed to provide an update on recent developments in the management of patients with advanced liver disease including chronic hepatitis C, cirrhosis, hepatocellular carcinoma and complications of psychosomatic issues in liver transplant candidates. Through a series of overview lectures and case presentations, participants will become familiar with the use of oral antiviral agents for HCV, the indications and outcomes with adult liver transplantation for HCC, advances in pediatric liver transplantation and potential clinical applications of regenerative medicine in transplantation.
The goal of this course is for the following objectives to be understood and utilized within your practice:
- When and who to treat with chronic HCV infection
- Efficacy and safety of novel oral antiviral agents in special patient populations including decompensated HCV cirrhosis and dialysis patients
- Diagnosis and treatment of psychosomatic issues in patients with liver disease
- Indications and outcomes with liver transplantation for patients with hepatocellular carcinoma
- Role of medical and palliative care in operable HCC
- Recent advances in liver tissue engineering and regenerative medicine with potential clinical applications
- Indications and outcomes with pediatric liver transplantation
- Advances in hot topics in infectious diseases including testing for Ebola virus infection and newly released vaccines
Accreditations & Credit Designation
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Michigan Medical School designates this live activity for a maximum of 6 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. An application has been submitted to the American Osteopathic Association for credits. Other credits by specialty may apply. Nurses: The Michigan State Board of Nursing recognizes the Accreditation Council for Continuing Medical Education (ACCME) as an approved provider of continuing medical education for nurses. CME credits awarded at this program may be applied to the 25 hour relicensing requirements, per Rule 2.a., Michigan State Board of Nursing. Social Work: An application has been submitted for CEs and an approval is pending with the Michigan Social Work Continuing Education Collaborative. Transplant Certification: Category I Continuing Education Points for Transplant Certification (CEPTCs) have been applied for through the American Board for Transplant Certification (ABTC).
|8:00||Introduction and Welcome
Robert J. Fontana, MD
|8:10||General Management of HCV
Anna Lok, MD
|8:40||HCV in Special Patient Populations: Decomps and ESRD
Robert J. Fontana, MD
|9:10||Psychosomatic Issues in Liver Transplant
Marijuana and Tobacco Addiction
Scott Winder, MD
|9:40||Questions & Answers|
|10:15||Indications and Outcomes with Liver Transplantation for HCC
Theodore H. Welling, MD
|10:45||Medical Management of Advanced HCC: Cost vs.
Neehar Parikh, MD
|11:15||Questions & Answers|
Case #1 – Antivirals in HCV
Case #2 – Antiviral Agents in Advanced HCV
Moderator: Robert J. Fontana, MD
Panel Discussion: Drs. Lok, Parikh and Welling
|1:00||Regenerative Medicine and Liver Tissue Engineering
Jason A. Wertheim, MD, PhD
|1:45||Advances in Pediatric Liver Transplantation
Frank DiPaolo, MD
|2:15||Update in Infectious Diseases: Ebola and Beyond
Daniel Kaul, MD
|2:45||Questions & Answers|
|3:00||Closing Remarks and Evaluation
Robert J. Fontana, MD